Brexpiprazole
- Generic Name
- Brexpiprazole
- Brand Names
- Rxulti, Rexulti
- Drug Type
- Small Molecule
- Chemical Formula
- C25H27N3O2S
- CAS Number
- 913611-97-9
- Unique Ingredient Identifier
- 2J3YBM1K8C
- Background
Brexpiprazole is an atypical antipsychotic and a novel D2 dopamine and serotonin 1A partial agonist called serotonin-dopamine activity modulator (SDAM). It has a high affinity for serotonin, dopamine and alpha (α)-adrenergic receptors. Although it is structurally similar to aripiprazole, brexpiprazole has different binding affinities for dopamine and seroton...
- Indication
Brexpiprazole is indicated as adjunctive therapy to antidepressants for the treatment of major depressive disorder in adults. It is also indicated for the treatment of schizophrenia in patients 13 years of age and older.
...
- Associated Conditions
- Agitation, Schizophrenia, Major Depressive Disorder (MDD)
- Associated Therapies
- -
Real-life Assessment of Brexpiprazole (Rexulti) in Schizophrenia and in Depressive Disorders
- Conditions
- First Posted Date
- 2023-07-27
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Dr. Albert Kar-Kin Chung
- Target Recruit Count
- 40
- Registration Number
- NCT05962216
- Locations
- 🇭🇰
Queen Mary Hospital, Hong Kong, Hong Kong
Open-label Brexpiprazole fMRI Trial in Adults With Major Depressive Disorder and Anxiety
Real-life Assessment of Abilify Maintena + Rexult in Schizophrenia
- Conditions
- Interventions
- First Posted Date
- 2021-12-23
- Last Posted Date
- 2023-07-05
- Lead Sponsor
- The University of Hong Kong
- Target Recruit Count
- 10
- Registration Number
- NCT05169268
- Locations
- 🇭🇰
Queen Mary Hospital, Hong Kong, Hong Kong
Optimized Predictive Treatment In Medications for Unipolar Major Depression (OPTIMUM-D)
- Conditions
- Interventions
- First Posted Date
- 2021-08-23
- Last Posted Date
- 2024-03-13
- Lead Sponsor
- Nova Scotia Health Authority
- Target Recruit Count
- 400
- Registration Number
- NCT05017311
- Locations
- 🇨🇦
University of British Columbia, Vancouver, British Columbia, Canada
🇨🇦University of Calgary, Calgary, Alberta, Canada
🇨🇦Queen's University, Kingston, Ontario, Canada
Brexpiprazole as Adjunctive Therapy in Adults With Major Depressive Disorder
- First Posted Date
- 2021-04-05
- Last Posted Date
- 2024-02-02
- Target Recruit Count
- 122
- Registration Number
- NCT04830215
- Locations
- 🇨🇦
Chatham-Kent Clinical Trials Research Centre, Chatham, Ontario, Canada
"Brexpiprazole (Rexulti™) Safety and Efficacy Among Filipino Patients (RAISE) - A Post Marketing Surveillance Program"
- Conditions
- Interventions
- First Posted Date
- 2020-11-24
- Last Posted Date
- 2020-12-01
- Lead Sponsor
- Otsuka Pharmaceutical, Inc., Philippines
- Target Recruit Count
- 300
- Registration Number
- NCT04641780
- Locations
- 🇵🇭
Otsuka (Philippines) Pharmaceutical Inc., Makati City, Metro Manila, Philippines
Brexpiprazole Treatment for Bipolar I Depression
- First Posted Date
- 2020-09-29
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Douglas Mental Health University Institute
- Target Recruit Count
- 58
- Registration Number
- NCT04569448
- Locations
- 🇨🇦
Jewish General Hospital, Montreal, Quebec, Canada
🇨🇦Douglas Mental Health University Institute, Montreal, Quebec, Canada
🇨🇦McMaster University, Hamilton, Ontario, Canada
Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder for Subjects That Have Completed Participation in 331-201-00148
- Conditions
- Interventions
- First Posted Date
- 2020-02-06
- Last Posted Date
- 2024-05-30
- Target Recruit Count
- 95
- Registration Number
- NCT04258839
- Locations
- 🇺🇸
APG Research, Orlando, Florida, United States
🇺🇸Cedar Health Research, Dallas, Texas, United States
🇺🇸Dothan Behavioral Medicine Clinic, Dothan, Alabama, United States
Evaluating the Safety and Tolerability of Brexpiprazole in the Treatment of Adults With Borderline Personality Disorder (BPD)
- First Posted Date
- 2019-12-04
- Last Posted Date
- 2024-10-03
- Target Recruit Count
- 201
- Registration Number
- NCT04186403
- Locations
- 🇺🇸
For additional information regarding sites, contact 844-687-8522, New York, New York, United States
Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder
- Conditions
- Interventions
- First Posted Date
- 2019-11-22
- Last Posted Date
- 2023-08-14
- Target Recruit Count
- 119
- Registration Number
- NCT04174365
- Locations
- 🇺🇸
For additional information regarding sites, Princeton, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.